The CRC Blueprint

My scientific approach to my own cancer – shared with you.

MSI-H / dMMR

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Phase 2 · randomised · 353 people · 6 sites in Netherlands · Recruiting now

August 7, 2026
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Phase 3 · randomised · 386 people · 1 site in China · Recruiting now

August 7, 2026
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Phase 2 · 60 people · 1 site in United States · Recruiting now

August 7, 2026
A Study Testing SOT109 for the First Time in Patients, to Assess How Safe SOT109 is, How Well it Works, and How the Body Handles it in Patients With Advanced Colorectal Cancer That Can Not be Removed by Surgery or is Metastatic

Phase 2 · randomised · 100 people · 3 sites in 2 countries · Opening soon

August 7, 2026
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

Phase 2 · randomised · 302 people · 109 sites in 22 countries · Running, not taking new patients

August 7, 2026